Literature DB >> 8545382

[Treatment of rheumatoid psoriasis with bromocriptine].

F Eulry1, H Mayaudon, D Lechevalier, B Bauduceau, L Ariche, H Ouakil, P Crozes, J Magnin.   

Abstract

Non-steroid anti-inflammatory drugs and/or gold salts were unsuccessful alone in providing symptom relief in three men with rheumatoid psoriasis. All three were treated with bromocriptine (5 mg/d in 2 doses) after verification of normal baseline and protirelin-stimulation prolactin levels. There was a beneficial effect in nocturnal pain relief, morning stiffness, the Lee and Ritchie scores and biological markers of inflammation. Two of the patients were able to return to regular work occupation after 15 and 45 days. In the third patient, bromocriptine was discontinued due to nausea and dizziness but was reintroduced successfully in fractionated doses after recurrence of the symptomatology. Treatment was continued without secondary adverse effects for 3 to 9 months providing continued symptom relief. Bromocriptine can be an effective adjuvant for the management of rheumatoid psoriasis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8545382

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  2 in total

1.  Serum prolactin levels in patients with psoriasis: Results of a pilot study.

Authors:  Gaytri Khatri; Vikram K Mahajan; Karaninder S Mehta; Krishan Kumar Sharma; Satya Bhushan; Pushpinder S Chauhan
Journal:  Indian J Med Res       Date:  2017-02       Impact factor: 2.375

Review 2.  Current guidelines for the drug treatment of ankylosing spondylitis.

Authors:  E Toussirot; D Wendling
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.